To the Editor:
In a retrospective study, the administration of antifibrinolytics and strict blood pressure control was reported to prevent hematoma growth in patients with spontaneous intracerebral hemorrhage (37). A combination of tranexamic acid and nicardipine was given intravenously to 156 patients. One group received a prolonged infusion of 1 g tranexamic acid over a period of 6 hours and the second group was given a rapid infusion of 2 g tranexamic acid over a period of 10 minutes. Hematoma growth was observed in 17.5 % of the 63 patients in the first group and in 4.3 % of 93 patients in the second group.
The most commonly used synthetic antifibrinolytics are epsilon-aminocaproic acid (EACA), tranexamic acid (AMCA) and para-aminobenzoic acid (PAMBA). On a molar basis AMCA is four to 10 times more potent than EACA and twice as strong as PAMBA (2, 26, 29, 31, 34). These antifibrinolytics have been shown to cross the blood-cerebrospinal fluid (CSF) barrier to reduce or inhibit the increased fibrinolytic activity of blood or CSF after aneurysmal subarachnoid hemorrhage (SAH) and to prolong and solidify experimental thrombosis (12, 15, 16, 30, 35). The therapeutic plasma concentration of synthetic antifibrinolytic drugs has been estimated to be more than 130 mg/L for EACA and more than 10 mg/L for AMCA, which requires an intravenous dosage of 24–36 g of EACA and 3–6 g of AMCA/ 24 hours (3, 14, 28). It is known that antifibrinolytic agents possess sympathomimetic properties and may, theoretically, induce vasoconstriction, possibly by acting via the adrenergic nerve terminals and thus deplete the stored catecholamines (1, 17, 24, 27, 32, 33). There have been several reports of thrombotic episodes, glomerular microthrombi, myopathy, myoglobinuria and cardiovascular complications following administration of antifibrinolytic drugs 4–8, 13, 18, 19, 20, 22, 23, 25, 36, 38, 40). Randomized controlled studies using antifibrinolytics in patients with SAH have shown increased delayed cerebral ischemic complications (9–11, 14, 15, 39). Some authors have suggested the use of antifibrinolytics in combination with calcium channel blockers (nicardipine, nimodipine) in the hope of reducing rebleeds as well as delayed cerebral ischemic complications in SAH (21). However, today the prime rationale for the use of antifibrinolytic drugs in SAH has disappeared (14).
In the present study, no serious adverse effects were noted (37). The occurrence of renal dysfunction in three patients and fatal myocardial infarction in two patients were considered to have no relationship with the administration of tranexamic acid. In my opinion, the authors have no basis for this assumption, and they have refrained from documenting the pharmacokinetics, toxicology, and important side effects of the drug. They simply refer to an “attached document” from the drug manufacturer stating that up to 2.5 g of tranexamic acid can be safely administered in a single dose and, therefore, settled for an arbitrary dose of 2 g. Patients who required surgery or who had a bad prognosis were not included, whereas 20 patients with history of renal disease, angina pectoris, and myocardial infarction were included. There is no mention of clinical outcomes in the report, and the only thing we learn from the study is that there was less hematoma growth. Who is the winner here, the patient or the drug company?
With regard to the potential serious side effects of tranexamic acid as documented in the literature, the therapeutic regimen for intracerebral hemorrhage described in this limited study should be disregarded until a carefully designed randomized controlled clinical trial has been conducted.
New York, New York
1. Anden NE, Henning M, Obianwu HO: Effect of epsilon aminocaproic acid on adrenergic nerve function and tissue monoamine levels. Acta Pharmacol Toxicol
2. Andersson L, Nilsson IM, Nilehn JE, Hedner U, Granstrand B, Melander B: Experimental and clinical studies on AMCA, the antifibrinolytically active isomer of p-aminomethyl cyclohexane carboxylic acid. Scand J Haematol
3. Andersson L, Eriksson O, Hedlund PO, Kjellman H, Lindqvist B: Special considerations with regard to the dosage of tranexamic acid in patients with chronic renal disease. Urol Res
4. Bergin JJ: Complications of therapy with epsilon-aminocaproic acid. Med Clin North Am
5. Biswas CK, Milligan DA, Agte SD, Kenward DH, Tilley PB: Acute renal failure and myopathy after treatment with aminocaproic acid. Br Med J
6. Britt CW, Light RR, Peters BH: Rhabdomyolysis during treatment with epsilon-aminocaproic acid. Arch Neurol
7. Charytan C, Purtilo D: Glomerular capillary thrombosis and acute renal failure after epsilon-aminocaproic acid therapy. N Engl J Med
8. Davies D, Howell DA: Tranexamic acid and arterial thrombosis. Lancet
9. Fodstad H: Tranexamic acid as therapeutic agent in aneurysmal subarachnoid haemorrhage: Clinical, laboratory and experimental studies.
Umea University Medical Dissertations, New Series No 60:1-74 1980.
10. Fodstad H: Antifibrinolytic treatment in subarachnoid haemorrhage: Present state. Acta Neurochir
11. Fodstad H, Forssell A, Liliequist B, Schannong M: Antifibrinolysis with tranexamic acid in aneurysmal subarachnoid hemorrhage: A consecutive controlled clinical trial. Neurosurgery
12. Fodstad H, Kok P, Algers G: Fibrinolytic activity of cerebral tissue after experimental subarachnoid haemorrhage: Inhibitory effect of tranexamic acid (AMCA). Acta Neurol Scand
13. Fodstad H, Liliequist B: Spontaneous thrombosis of ruptured intracranial aneurysms during treatment with tranexamic acid (AMCA). Report of three cases. Acta Neurochir
14. Fodstad H, Ljunggren B: Antifibrinolytic drugs in subarachnoid hemorrhage, in Sawaya R (ed): Fibrinolysis and the Central Nervous System.
Philadelphia, Hanley & Belfus, 1990, pp 257–273.
15. Fodstad H, Nilsson IM: Coagulation and fibrinolysis in blood and cerebrospinal fluid after aneurysmal subarachnoid haemorrhage: Effect of tranexamic acid (AMCA). Acta Neurochir
16. Fodstad H, Pilbrant A, Schannong M, Stromberg S: Determination of tranexamic acid and fibrin/fibrinogen degradation products in cerebrospinal fluid after aneurysmal subarachnoid haemorrhage. Acta Neurochir
17. Garrett J, Branco D: Indirect sympathomimetic actions of E-amini-caproic acid (EACA): Role of the adrenal medulla. Arch Int Pharmacodyn Ther
18. Gilligan BS: Myoglobinuria with muscle weakness associated with epsilonaminocaproic acid therapy, in Kakulas BA (ed): Clinical Studies in Myology. Part 2.
New York, Elsevier, 1973, pp 589–593.
19. Gralnick HR, Greipp P: Thrombosis with epsilon aminocaproic acid therapy. Am J Clin Pathol
20. Hoffman EA, Koo AH: Cerebral thrombosis associated with Amicar therapy. Radiology
21. Kassell NF, Haley EC, Torner JC: Antifibrinolytic therapy in the treatment of aneurysmal subarachnoid hemorrhage. Clin Neurosurg
22. Kennard C, Henson RA: Myopathy due to epsilon aminocaproic acid. Muscle Nerve
23. Kato N, Morimatsu M, Tanaka K, Horie A: Effects of trans-4-aminomethyl-cyclohexane carboxylic acid as an antifibrinolytic agent on arterial wall and experimental atherosclerotic lesions in rabbits. Thromb Diath Haemorrh
24. Lippmann W, Wishnick MM: Effects of the administration of epsilon aminocaproic acid on catecholamine and serotonin levels in the rat and dog. J Pharmacol Exp Ther
25. Mackay AR, Hoi Sang U, Weinstein PR: Myopathy associated with epsilon-aminocaproic acid (EACA) therapy: Report of two cases. J Neurosurg
26. Maki M, Beller FK: Comparative studies of fibrinolytic inhibitors in vitro. Thromb Diath Haemorrh
27. Marmo E, Di Nola R, Rossi F: Cardiovascular effects of of antifibrinolytic drugs. Res Commun Chem Pathol Pharmacol
28. McNichol GP, Fletcher AP, Alkjaerstig N, Sherry S: The absorption, distribution and excretion of e-aminocaproic acid following oral or intravenous administration in man. J Lab Clin Med
29. Melander B, Gliniecki G, Granstrand B, Hansoff G: Biochemistry and toxicology of Amicapron; the antifibrinolytically active isomer of AMCHA. (A comparative study with e-aminocaproic acid.) Acta Pharmacol Toxicol
30. Mihara H, Fuji T, Okamoto S: Fibrinolytic activity of cerebrospinal fluid and the development of artificial cerebral haemorrhage. Thromb Diath Haemorrh
31. Nilsson IM: Clinical pharmacology of aminocaproic and tranexamic acid. J Clin Pathol
33 [Suppl 14]:41–47, 1980.
32. Norrman SR: The sympathomimetic action of trans-4-amino-methyl cyclohexane carboxylic acid (AMCA, Cyclocapron) in anaesthetized cats. Data on file, AB Kabi, Stockholm, 1975.
33. Obianwu HO: Disposition of 3 H-epsilon aminocaproic acid and its interaction with adrenergic neurons. Br J Pharmacol
34. Okamoto S, Oshiba S, Mihara H, Okamoto U: Synthetic inhibitors of fibrinolysis: In vitro and in vivo mode of action. Ann NY Acad Sci
35. Patterson RH, Harpel P: The effect of epsilon-aminocaproic acid and tranexamic acid on thrombus size and strength in a simulated arterial aneurysm. J Neurosurg
36. Rydin E, Lundberg PO: Tranexamic acid and intracranial thrombosis. Lancet
37. Sorimachi T, Fujii Y, Morita K, Tanaka R: Rapid administration of antifibrinolytics and strict blood pressure control for intracerebral hemorrhage. Neurosurgery
38. Vanneste JA, van Wijngaarden GK: Epsilon-aminocaproic acid myopathy: Report of a case and literature review. Eur Neurol
39. Vermeulen M, Lindsay KW, Murray GD, Cheah H, Hijdra A, Muizelaar JP, Schannong M, Teasdale GM, van Crevel H, van Gijn J: Antifibrinolytic treatment in subarachnoid hemorrhage. N Engl J Med
40. Yamaura A, Nakamura T, Makino H: Cerebral complication of antifibrinolytic therapy in the treatment of ruptured intracranial aneurysm. Eur Neurol